Cargando…
European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib
Xeljanz(®) (tofacitinib) is an oral small-molecule inhibitor that reversibly inhibits Janus-activated kinase (JAK)-dependent cytokine signaling, thus reducing inflammation. As a result of these mechanisms, effects on the immune system such as a moderate decrease in the total lymphocyte count, a dose...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743127/ https://www.ncbi.nlm.nih.gov/pubmed/29317823 http://dx.doi.org/10.2147/TCRM.S138677 |